a 3-year audit of radiographer screen film reading3年审计的放射线技师电影屏幕阅读.pdfVIP

Available online /supplements/6/S1 Abstracts from Symposium Mammographicum 2004 Edinburgh International Conference Centre, 19–20 July 2004 1 Developing new treatments for breast cancer D Lane University of Dundee, UK and Cyclacel Ltd, UK Breast Cancer Res 2004, 6(Suppl 1):P1 (DOI 10.1186/bcr820) Twenty-five years after its first description the p53 protein has A key regulator is Mdm2, an E3 ubiquitin ligase, that binds and been shown to play a key role in both cancer and ageing. The p53 ubiquitinates p53 and directs its degradation via the proteosome. protein is activated by many different stress pathways, including Small potent peptides that can block the p53 Mdm2 interaction oncogene action and DNA damage. The elucidation of the p53 and activate the p53 response have been described. Growing response, which is aberrant in most cancers (including breast, selections of lead small molecules that mimic the action of these lung, stomach and colorectal cancer), has provided many new peptides have also been recently discovered. Cell-based screens targets for drug development and p53 gene therapy is now have revealed that inhibitors of nuclear export and inhibitors of approved in China. In tumours where p53 is mutant small transcription (one of which is in clinical trial) can also activate the molecules may be able to restore its function. In many tumours the p53 response therapeutically. The pharmaceutical regulation of wild-type p53 gene remains intact but its function is compromised th